哮喘患者呼出气冷凝液及诱导痰中超敏C反应蛋白相关性研究

The relevance of high-sensitivity C-reactive protein in exhaled breath condensate and induced sputum in asthma

目的探讨哮喘患者呼出气冷凝液和诱导痰中超敏C反应蛋白含量相关性。方法随机选择60位哮喘患者,分别在急性期和缓解期检测超敏C反应蛋白在呼出气冷凝液(exhaled breath condensate,EBC)及诱导痰(induced sputum,IS)中含量,研究两者相关性。结果急性期哮喘患者EBC中hs-CRP的含量(重度组0.32±0.02 mg/L,中度组0.28±0.04 mg/L)均高于缓解期含量(重度组0.20±0.04 mg/L,中度组0.18±0.02 mg/L;均P<0.05)及健康对照组0.08±0.01 mg/L(P<0.05);急性期哮喘患者IS中hs-CRP含量(重度组2.7±0.1 mg/L,中度组2.0±0.16 mg/L)也均高于缓解期(重度组1.2±0.15 mg/L,中度组1.4±0.12 mg/L;均P<0.05)及健康对照组0.4±0.05 mg/L(P<0.05);中、重度组EBC和诱导痰中hs-CRP含量在治疗前、后均具有显著正相关性。结论哮喘患者EBC中超敏C反应蛋白检测可用于评价气道炎症水平,其临床价值可与诱导痰中超敏C反应蛋白检测相媲美。

Objective To investigate the relevance of high-sensitivity C-reactive protein in exhaled breath condensate and induced sputum in asthma. Methods 60 patients with asthma in the acute phase and remission period were selected randomly,were used to detect the high-sensitivity C-reactlve protein in exhaled breath condensate （EBC）and induced sputum（IS）. And the correlations between them were compared. Results In the acute phase, hs-CRP content in EBC of asthma（ severe group 0.32 ± 0. 02 mg/L, medium group 0. 28 ±0. 04 mg/L）was higher than the remission period （severe group 0. 20 ± 0. 04 mg/L, medium group 0.18 ± 0. 02 mg/L; all P 〈 0. 05） and in healthy control group（0.08 ± 0.01 mg/L,P 〈 0.05 ）. In the acute phase, hs-CRP content in IS of asthma（ severe group 2.7 ± 0. 1 mg/L, medium group 2.0 ± 0. 16 mg/L）was higher than the remission period（ severe group 1.2 ± 0. 15 mg/L,medium group 1.4 ±0. 12 mg/L; all P 〈 0. 05 ） and in healthy control group （0.4 ± 0. 05 mg/L, P 〈 0. 05 ）. For the medium and severe groups ： before and after the treatments,EBC and induced sputum concentrations of hs-CRP had a significant positive correlation. Conclusion The detecting of high-sensitivity C-reactive protein in the exhaled breath condensate in asthma can be used to evaluate the level of airway inflammation. It was the clinical value,It is useful in detecting the level of high-sensitivity C-reactive protein in IS.